

INDEX GUIDELINE

SOLACTIVE DIGITAL HEALTH INDEX

Version 1.1

24 May 2024



TABLE OF CONTENTS

In	troduc	tion	3
1.	In	dex Specifications	4
	1.1.	Scope of the Index	4
	1.2.	Identifiers and Publications	4
	1.3.	Initial Level of the Index	5
	1.4.	Prices and calculation frequency	5
	1.5.	Licensing	5
2.	In	dex Selection	6
	2.1.	Index Universe Requirements	6
	2.2.	Selection of the Index Components	6
	2.3.	Weighting of the Index Components	7
3.	R	ebalance	8
	3.1.	Ordinary Rebalance	8
	3.2.	Extraordinary Rebalance	8
4.	Ca	alculation of the Index	g
	4.1.	Index formula	g
	4.2.	Accuracy	g
	4.3.	Adjustments	10
	4.4.	Corporate actions	10
	4.5.	Recalculation	11
	4.6.	Market Disruption	11
5.	М	iscellaneous	12
	5.1.	Discretion	12
	5.2.	Methodology Review	12
	5.3.	Changes in calculation method	12
	5.4.	Termination	13
	5.5.	Extraordinary termination	13
	5.6.	Oversight	13
6.	D	efinitions	14
7.	Н	istory of Index Changes	16
Сс	ntact		20



INTRODUCTION

This document (the "GUIDELINE") is to be used as a guideline with regard to the composition, calculation and maintenance of the Solactive Digital Health Index (the "INDEX"). Any amendments to the rules made to the GUIDELINE are approved by the OVERSIGHT COMMITTEE specified in Section 5.5. The INDEX is owned, calculated, administered and published by Solactive AG ("Solactive") assuming the role as administrator (the "INDEX ADMINISTRATOR") under the Regulation (EU) 2016/1011 (the "BENCHMARK REGULATION" or "BMR"). The name "Solactive" is trademarked.

The text uses defined terms which are formatted with "SMALL CAPS". Such Terms shall have the meaning assigned to them as specified in Section 6 (Definitions).

The Guideline and the policies and methodology documents referenced herein contain the underlying principles and rules regarding the structure and operation of the INDEX. Solactive does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the INDEX nor the level of the INDEX at any certain point in time nor in any other respect. Solactive strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the INDEX. The publication of the INDEX by Solactive does not constitute a recommendation for capital investment and does not contain any assurance or opinion of Solactive regarding a possible investment in a financial instrument based on this INDEX.



1. INDEX SPECIFICATIONS

1.1. SCOPE OF THE INDEX

Category	Description	
Asset Class	Equity	
Stratogy	Representation of securities from developed markets that	
Strategy	generate revenue in digital health related industries.	
Regional Allocation	Developed Markets	
Rebalancing Fee	n/a	
Rebalancing Frequency	Quarterly	

1.2. IDENTIFIERS AND PUBLICATIONS

The INDEX is published under the following identifiers:

Name	ISIN	Currency	Туре	RIC	BBG ticker
Solactive Digital Health Index PR	DE000SL0C2C3	EUR	PR*	.SOLDIHPR	SOLDIHPR
Solactive Digital Health Index NTR	DE000SL0C2D1	EUR	NTR*	.SOLDIHNR	SOLDIHNR
Solactive Digital Health Index GTR	DE000SL0C4S5	EUR	GTR*	.SOLDIHTR	SOLDIHTR
Solactive Digital Health Index AR	DE000SL0CX94	EUR	AR*	.SOLDIHAR	SOLDIHAR

^{*}PR, NTR, and GTR means that the Index is calculated as price return, net total return, and gross total return index as described in the Equity Index Methodology, which is available on the Solactive website: https://www.solactive.com/documents/equity-index-methodology/

The INDEX is published on the website of the INDEX ADMINISTRATOR (www.solactive.com) and is, in addition, available via the price marketing services of Boerse Stuttgart GmbH and may be distributed to all of its affiliated vendors. Each vendor decides on an individual basis as to whether it will distribute or display the INDEX via its information systems.

Any publication in relation to the INDEX (e.g. notices, amendments to the GUIDELINE) will be available at the website of the INDEX ADMINISTRATOR: https://www.solactive.com/news/announcements/.

^{**}AR means that the Index is calculated as an adjusted return index, following the formula specified in Section 4.



1.3. INITIAL LEVEL OF THE INDEX

The initial level of the INDEX on the 08/05/2006, the START DATE, is 1000. Historical values from the 26/04/2021, the LIVE DATE, will be recorded in accordance with Article 8 of the BMR. Levels of the INDEX published for a period prior to the LIVE DATE have been back-tested.

1.4. PRICES AND CALCULATION FREQUENCY

The level of the INDEX is calculated on each CALCULATION DAY from 9:00 a.m. to 10:50 p.m. CET based on the TRADING PRICES on the EXCHANGES on which the INDEX COMPONENTS are listed. TRADING PRICES of INDEX COMPONENTS not listed in the INDEX CURRENCY are converted using the current Intercontinental Exchange (ICE) spot foreign exchange rate. Should there be no current Trading Price for an INDEX COMPONENT, the later of: (i) the most recent Closing Price; or (ii) the last available Trading Price for the preceding Trading Day is used in the calculation.

In addition to the intraday calculation a closing level of the INDEX for each CALCULATION DAY is also calculated. This closing level is based on the CLOSING PRICES for the INDEX COMPONENTS on the respective EXCHANGES on which the INDEX COMPONENTS are listed. The CLOSING PRICES of INDEX COMPONENTS not listed in the INDEX CURRENCY are converted using the 04:00 p.m. London time WM Fixing quoted by Reuters. If there is no 04:00 p.m. London time WM Fixing for the relevant CALCULATION DAY, the last available 04:00 p.m. London time WM Fixing will be used for the closing level calculation.

1.5. LICENSING

Licenses to use the INDEX as the underlying value for financial instruments, investment funds and financial contracts may be issued to stock exchanges, banks, financial services providers and investment houses by SOLACTIVE.



2. INDEX SELECTION

On each Selection Day, the Index Administrator will revise the composition of the Index.

In a first step, the INDEX ADMINISTRATOR determines the INDEX UNIVERSE in accordance with Section 2.1. The INDEX UNIVERSE comprises all those financial instruments which fulfill the INDEX UNIVERSE REQUIREMENTS (as specified in Section 2.1) and will constitute a starting pool from which the components of the INDEX will be selected. Based on this INDEX UNIVERSE, the new composition of the INDEX will be determined by applying the rules outlined in Section 2.2.

Each new INDEX COMPONENT will be assigned a weight as described in Section 2.3.

2.1. INDEX UNIVERSE REQUIREMENTS

The INDEX UNIVERSE is comprised of all financial instruments which fulfill the below requirements (the "INDEX UNIVERSE REQUIREMENTS"):

• Part/ Component of the **GBS INDEX UNIVERSE** of the *Solactive GBS Developed Markets Large & Mid Cap USD Index (ISIN:* DE000SLA41B6), on a SELECTION DAY.

The determination of the INDEX UNIVERSE is fully rule-based and the INDEX ADMINISTRATOR cannot make any discretionary decisions.

2.2. SELECTION OF THE INDEX COMPONENTS

Based on the INDEX UNIVERSE, the initial composition of the INDEX as well as any selection for an ORDINARY REBALANCE is determined on the Selection Day in accordance with the following rules:

• SOLACTIVE evaluates all companies in the respective INDEX UNIVERSE based on the criteria outlined in the table below. The evaluation is based on data provided by the ESG DATA PROVIDER:

	Theme	Exclusion criterion
Norm-Based Research UN Global Compact		Violation
		0% Controversial Weapons < OR > 10% Civilian
	Aerospace & Defense / Weapons	Firearms < OR > 10% Military Equipment and
Contain Donal Companies		Services < OR > Classified in the Industry
Sector-Based Screening		"Aerospace & Defense"
	Tobacco	10% Production <or> 10% Services <or> 10%</or></or>
		Retail Revenues



	Coal	10% Thermal Coal Extraction
		10% Arctic Oil & Gas Exploration
	Unconventional Oil & Gas	Extraction <or> 10% Oil Sands Extraction <or></or></or>
		10% Shale Energy Extraction
	Conventional Oil & Gas	10% Oil & Gas Production < OR > 10% Oil & Gas
		Supporting Products/Services
		25% Nuclear Production < OR > 25% Nuclear
		Supporting Products/Services < OR > 25%
	Electricity Generation	Nuclear Distribution < OR > 10% Thermal Coal
		Power Generation < OR > 25% Oil & Gas
		Generation
Explanation: % figures refer	to revenue threshold (for dearee of	involvement) above which criterion is breached

- Eligible companies must derive any aggregated revenues from the sub-industries listed in the table in Appendix A. The listed sub-industries are based on the Factset Revere Business Industry Classification System (RBICS).
- A minimum Average Daily Value Traded of at least EUR 10,000,000 over 3 months prior to and including the SELECTION DAY.
- In case of multiple share classes of the same company, only the share class with the highest liquidity is considered. Liquidity is measured as the AVERAGE DAILY VALUE TRADED over 3-months prior to and including the SELECTION DAY in EUR.
- The remaining securities are then ranked in descending order based on their aggregated revenues derived from the RBICS sub-industries listed in the table in Appendix A. The top 30 stocks with the highest aggregated revenues from the RBICS sub-industries are then selected as INDEX COMPONENTS.

The selection of the INDEX COMPONENTS is fully rule-based and the INDEX ADMINISTRATOR cannot make any discretionary decision.

2.3. WEIGHTING OF THE INDEX COMPONENTS

On each Selection Day each Index Component is assigned an equal weight.



3. REBALANCE

3.1. ORDINARY REBALANCE

In order to reflect the new selection of the INDEX COMPONENTS determined on the SELECTION DAY (in accordance with Section 2.1 and 2.2) the INDEX is adjusted on the REBALANCE DAY after CLOSE OF BUSINESS.

This is carried out by implementing the shares as determined on the FIXING DAY based on the weights calculated on the Selection DAY.

For more information on the rebalance procedure please refer to the Equity Index Methodology, which is incorporated by reference and available on the SOLACTIVE website: https://www.solactive.com/documents/equity-index-methodology/.

SOLACTIVE will publish any changes made to the INDEX COMPONENTS with sufficient notice before the REBALANCE DAY on the SOLACTIVE webpage under the section "Announcement", which is available at https://www.solactive.com/news/announcements/

3.2. EXTRAORDINARY REBALANCE

The INDEX is not rebalanced extraordinarily.



4. CALCULATION OF THE INDEX

4.1. INDEX FORMULA

The INDEX is calculated as a price return, net total return and gross total return Index.

The calculation is performed according to the Equity Index Methodology, which is available on the Solactive website: https://www.solactive.com/documents/equity-index-methodology/. The standard index formula stipulates that the level of the INDEX changes based on the change of the prices of its INDEX COMPONENTS taking into account their weight in the INDEX and any currency conversion in case the price of an INDEX COMPONENT is quoted in a currency other than the INDEX CURRENCY.

Any dividends or other distributions are reinvested back into the INDEX COMPONENT paying the dividend or other distribution at the opening of the effective date (the so called ex-date) of the payment of such dividend or other distribution.

A more detailed description of the mechanics of the index calculation formula can be found in the Equity Index Methodology under Section 1.2.

For the construction of the adjusted return version a management fee of 5% per annum is deducted on each INDEX CALCULATION DAY from the NTR Index version. The management fee will be applied in compliance with the following formula:

$$Index(t) = Index(t-1) * [\frac{NTR(t)}{NTR(t-1)} - AF \times \frac{Days(t-1,t)}{365}]$$

Where

Index = Level of the adjusted return version on a Calculation Day t

NTR = Level of the NTR Index version on a Calculation Day t

Days = The number of calendar days between CALCULATION DAY t-1 (excluding) and CALCULATION DAY t (including)

AF = The adjustment factor of 5%

4.2. ACCURACY

The level of the INDEX will be rounded to two decimal places. TRADING PRICES and foreign exchange rates will be rounded to six decimal places.



4.3. ADJUSTMENTS

Under certain circumstances, an adjustment of the INDEX may be necessary between two regular REBALANCE DAYS. Such adjustment has to be made if a corporate action (as specified in Section 4.4 below) in relation of an INDEX COMPONENT occurs. Such adjustment may have to be done in relation to an INDEX COMPONENT and/or may also affect the number of INDEX COMPONENTS and/or the weighting of certain INDEX COMPONENTS and will be made in compliance with the Solactive Equity Index Methodology, which is incorporated by reference and available on the Solactive website: https://www.solactive.com/documents/equity-index-methodology/.

SOLACTIVE will announce the INDEX adjustment giving a notice period of at least two TRADING DAYS (with respect to the affected INDEX COMPONENT) on the SOLACTIVE website under the Section "Announcements", which is available at https://www.solactive.com/news/announcements/. The INDEX adjustments will be implemented on the effective day specified in the respective notice.

4.4. CORPORATE ACTIONS

As part of the INDEX maintenance Solactive will consider various events — also referred to as corporate actions — which result in an adjustment to the INDEX between two regular REBALANCE DAYS. Such events have a material impact on the price, weighting or overall integrity of INDEX COMPONENTS. Therefore, they need to be accounted for in the calculation of the INDEX. Corporate actions will be implemented from the cum-day to the ex-day of the corporate action, so that the adjustment to the INDEX coincides with the occurrence of the price effect of the respective corporate action.

Adjustments to the INDEX to account for corporate actions will be made in compliance with the Equity Index Methodology, which is available on the Solactive website: https://www.solactive.com/documents/equity-index-methodology/. This document contains for each corporate action a brief definition and specifies the relevant adjustment to the INDEX variables.

While Solactive aims at creating and maintaining its methodology for treatment of corporate actions as generic and transparent as possible and in line with regulatory requirements, it retains the right in accordance with the Equity Index Methodology to deviate from these standard procedures in case of any unusual or complex corporate action or if such a deviation is made to preserve the comparability and representativeness of the INDEX over time.

SOLACTIVE considers following, but not conclusive, list of corporate actions as relevant for INDEX maintenance:

- Cash Distributions (e.g. payment of a dividend)
- Stock distributions (e.g. payment of a dividend in form of additional shares)
- > Stock distributions of another company (e.g. payment of a dividend in form of additional shares of another company (e.g. of a subsidiary))
- > Share splits (company's present shares are divided and therefore multiplied by a given factor)



- Reverse splits (company's present shares are effectively merged)
- Capital increases (such as issuing additional shares)
- > Share repurchases (a company offer its shareholders the option to sell their shares to a fixed price)
- > Spin-offs (the company splits its business activities into two or more entities and distributes new equity shares in the created entities to the shareholders of the former entity)
- Mergers & Acquisitions (transaction in which the ownership of a company (or other business organizations) are transferred or consolidated with other entities, e.g. fusion of two or more separate companies into one entity)
- Delistings (company's shares are no longer publicly traded at a stock exchange)
- Nationalization of a company (effective control of a legal entity is taken over by a state)
- > Insolvency

4.5. RECALCULATION

SOLACTIVE makes the greatest possible efforts to accurately calculate and maintain its indices. However, errors in the determination process may occur from time to time for variety reasons (internal or external) and therefore, cannot be completely ruled out. SOLACTIVE endeavors to correct all errors that have been identified within a reasonable period of time. The understanding of "a reasonable period of time" as well as the general measures to be taken are generally depending on the underlying and is specified in the Solactive Correction Policy, which is incorporated by reference and available on the SOLACTIVE website: https://www.solactive.com/documents/correction-policy/.

4.6. MARKET DISRUPTION

In periods of market stress Solactive calculates its indices following predefined and exhaustive arrangements as described in the Solactive Disruption Policy, which is incorporated by reference and available on the Solactive website: https://www.solactive.com/documents/disruption-policy/. Such market stress can arise due to a variety of reasons, but generally results in inaccurate or delayed prices for one or more INDEX COMPONENTS. The determination of the INDEX may be limited or impaired at times of illiquid or fragmented markets and market stress.



5. MISCELLANEOUS

5.1. DISCRETION

Any discretion which may need to be exercised in relation to the determination of the INDEX (for example the determination of the INDEX UNIVERSE (if applicable), the selection of the INDEX COMPONENTS (if applicable) or any other relevant decisions in relation to the INDEX) shall be made in accordance with strict rules regarding the exercise of discretion or expert judgement.

5.2. METHODOLOGY REVIEW

The methodology of the INDEX is subject to regular review, at least annually. In case a need of a change of the methodology has been identified within such review (e.g. if the underlying market or economic reality has changed since the launch of the INDEX, i.e. if the present methodology is based on obsolete assumptions and factors and no longer reflects the reality as accurately, reliably and appropriately as before), such change will be made in accordance with the Solactive Methodology Policy_which is incorporated by reference and available on the SOLACTIVE website: https://www.solactive.com/documents/methodology-policy/.

Such change in the methodology will be announced on the SOLACTIVE website under the Section "Announcement", which is available at https://www.solactive.com/news/announcements/. The date of the last amendment of this INDEX is contained in this GUIDELINE.

5.3. CHANGES IN CALCULATION METHOD

The INDEX ADMINISTRATOR shall apply the method described above for the composition and calculation of the INDEX. However, it cannot be excluded that the market environment, supervisory, legal and financial or tax reasons may require changes to be made to this method. The INDEX ADMINISTRATOR may also make changes to the terms and conditions of the INDEX and the method applied to calculate the INDEX that it deems to be necessary and desirable in order to prevent obvious or demonstrable error or to remedy, correct or supplement incorrect terms and conditions. The INDEX ADMINISTRATOR is not obliged to provide information on any such modifications or changes. Despite the modifications and changes, the INDEX ADMINISTRATOR will take the appropriate steps to ensure a calculation method is applied that is consistent with the method described above.



5.4. TERMINATION

Solactive makes the greatest possible efforts to ensure the resilience and continued integrity of its indices over time. Where necessary, Solactive follows a clearly defined and transparent procedure to adapt Index methodologies to changing underlying markets (see Section 5.2 "Methodology Review") in order to maintain continued reliability and comparability of the indices. Nevertheless, if no other options are available the orderly cessation of the INDEX may be indicated. This is usually the case when the underlying market or economic reality, which an index is set to measure or to reflect, changes substantially and in a way not foreseeable at the time of inception of the index, the index rules, and particularly the selection criteria, can no longer be applied coherently or the index is no longer used as the underlying value for financial instruments, investment funds and financial contracts.

Solactive has established and maintains clear guidelines on how to identify situations in which the cessation of an index is unavoidable, how stakeholders are to be informed and consulted and the procedures to be followed for a termination or the transition to an alternative index. Details are specified in the Solactive Termination Policy, which is incorporated by reference and available on the Solactive website: https://www.solactive.com/documents/termination-policy/.

5.5. EXTRAORDINARY TERMINATION

In the event the level of the ADJUSTED RETURN INDEX is calculated as zero or below zero (negative) the ADJUSTED RETURN INDEX will be terminated. Solactive will announce such termination on its website www.solactive.com as soon as reasonably possible after the ADJUSTED RETURN INDEX is calculated as zero or below zero.

For Clarification, Solactive may terminate indices for other reasons and in accordance with Solactive's policies.

5.6. OVERSIGHT

An oversight committee composed of staff from Solactive and its subsidiaries (the "**Oversight Committee**") is responsible for decisions regarding any amendments to the rules of the INDEX. Any such amendment, which may result in an amendment of the Guideline, must be submitted to the Oversight Committee for prior approval and will be made in compliance with the Methodology Policy, which is available on the Solactive website: https://www.solactive.com/documents/methodology-policy/.



6. DEFINITIONS

"ADJUSTED RETURN INDEX" is the AR Index as defined in section 1.2.

"Average Daily Value Traded" means, in respect of an INDEX COMPONENT, the sum of Daily Value Traded over the specified period divided by the number of Trading Days that fall in the specified period.

"BENCHMARK REGULATION" shall have the meaning as defined in Section "Introduction".

"BMR" shall have the meaning as defined in Section "Introduction".

"Business Day" is any weekday from Monday through Friday.

"CALCULATION DAY" is every weekday from Monday to Friday.

"CLOSE OF BUSINESS" is the calculation time of the closing level of the INDEX as outlined in Section 1.4.

The "CLOSING PRICE" in respect of an INDEX COMPONENT and a TRADING DAY is a security's final regular-hours TRADING PRICE published by the EXCHANGE and determined in accordance with the EXCHANGE regulations. If the EXCHANGE has no or has not published a CLOSING PRICE in accordance with the EXCHANGE rules for an INDEX COMPONENT, the last TRADING PRICE will be used.

"DAILY VALUE TRADED" means, in respect of an INDEX COMPONENT and a TRADING DAY, the product of (i) the CLOSING PRICE of such INDEX COMPONENT and (ii) the volume traded (measured as a number of shares) of such INDEX COMPONENT on the EXCHANGE during such TRADING DAY.

"ELIGIBLE REBALANCE DAY" is each day that is a TRADING DAY at the New York Stock Exchange, the London Stock Exchange, the EUREX Exchange and the Tokyo Stock Exchange.

"ESG DATA PROVIDER" is Sustainalytics. For more information, please visit: https://www.sustainalytics.com/.

"EXCHANGE" is with respect to the INDEX and every INDEX COMPONENT, the respective exchange where the INDEX COMPONENT has its listing as determined in accordance with the rules in Section 2.

"FIXING DAY" is SELECTION DAY.

The "FREE FLOAT" is with regard to each of the securities fulfilling the Index Component Requirements on a SELECTION DAY the share class-specific fraction of the total number of shares of such share class issued that are available for trading by market participants and not locked-in by long term holders, as sourced from data vendors.

The "FREE FLOAT MARKET CAPITALIZATION" is with regard to each of the securities fulfilling the Index Component Requirements on a SELECTION DAY the share class-specific free float market capitalization. It is calculated as the multiplication of the shares outstanding in FREE FLOAT (as sourced from data vendors) with the CLOSING PRICE of the share class as of the respective SELECTION DAY.

"GBS INDEX UNIVERSE" is the INDEX UNIVERSE as defined in the guideline of the Solactive Global Benchmark Series (https://solactive.com/downloads/Guideline-Solactive-GBS-Benchmark-Series.pdf) for the for the GBS Index specified in Section 2.1.



- "GUIDELINE" shall have the meaning as defined in Section "Introduction".
- "INDEX" shall have the meaning as defined in Section "Introduction".
- "INDEX ADMINISTRATOR" shall have the meaning as defined in Section "Introduction".
- "INDEX COMPONENT" is each security reflected in the INDEX.
- "INDEX COMPONENT REQUIREMENTS" shall have the meaning as defined in Section 2.2.
- "INDEX CURRENCY" is the currency specified in the column "Currency" in the table in Section 1.2.
- "INDEX UNIVERSE REQUIREMENTS" shall have the meaning as defined in Section 2.1.
- "INDEX UNIVERSE" is the sum of all financial instruments which fulfill the INDEX UNIVERSE REQUIREMENTS.
- "LIVE DATE" shall have the meaning as defined in Section 1.3.
- "Oversight Committee" shall have the meaning as defined in Section 5.5.
- "REBALANCE DAY" is the first Wednesday in February, May, August and November. If that day is not an ELIGIBLE REBALANCE DAY the REBALANCE DAY will be the immediately following ELIGIBLE REBALANCE DAY.
- "SELECTION DAY" is 20 Business Days before the Rebalance Day.
- "Shares outstanding" are all the shares of a corporation or financial asset that have been authorized, issued, and purchased by investors. This includes shares owned by the company's corporate officers and insiders, as well as those held by the public.
- "SOLACTIVE" shall have the meaning as defined in Section "Introduction".
- "START DATE" shall have the meaning as defined in Section 1.3.
- "TRADING DAY" is with respect to an INDEX COMPONENT included in the INDEX at the REBALANCE DAY and every INDEX COMPONENT included in the INDEX at the CALCULATION DAY immediately following the REBALANCE DAY (for clarification: this provision is intended to capture the TRADING DAYS for the securities to be included in the INDEX as new INDEX COMPONENTS with close of trading on the relevant EXCHANGE on the REBALANCE DAY) a day on which the relevant EXCHANGE is open for trading (or a day that would have been such a day if a market disruption had not occurred), excluding days on which trading may be ceased prior to the scheduled EXCHANGE closing time and days on which the EXCHANGE is open for a scheduled shortened period. The INDEX ADMINISTRATOR is ultimately responsible as to whether a certain day is a TRADING DAY.

The "TRADING PRICE" in respect of an INDEX COMPONENT and a TRADING DAY is the most recent published price at which the INDEX COMPONENT was traded on the respective EXCHANGE.



7. HISTORY OF INDEX CHANGES

Version	Date	Description
1.0	26 April 2021	Index Guideline creation (<i>initial version</i>)
1.1	24 May 2024	Addition of the EXTRAORDINARY TERMINATION section (5.5) and clarification of the ADJUSTED RETURN INDEX calculation formula



ANNEX A

Level	Number	Name
Subindustry	351510151515	Healthcare Management Software
Subindustry	351510151520	Healthcare Operations Support Software
Subindustry	351510151525	Other Healthcare and Pharma Industry Software
Subindustry	351510151530	Patient Data Management Software
Subindustry	351510252510	Healthcare IT Services
Subindustry	351515151510	Imaging Laboratories
Subindustry	351520151010	Analytical and Bioanalytical Services
Subindustry	351520201010	Drug Delivery Technology Development
Subindustry	351520251515	Scientific Analytical Instruments
Subindustry	351525101510	Diversified Medical Device OEMs
Subindustry	352010101010	Genetic Molecular Diagnostic Test Kits
Subindustry	352010101015	Home Testing Clinical Diagnostics Devices
Subindustry	352010101020	Other Chemistry Clinical Diagnostics Devices
Subindustry	352010101025	Point of Care Testing Kits
Subindustry	352010101510	General Clinical Diagnostics Devices
Subindustry	352010101515	Immunoassays Clinical Diagnostics Devices
Subindustry	352010151010	Infusion Therapy Devices
Subindustry	352010151510	Other Drug Delivery Devices
Subindustry	352010152010	Transdermal Delivery Devices



Subindustry352015101010Cardiology Non-Surgical DevicesSubindustry352015101510Cardiology Surgical DevicesSubindustry352015101510Joint Replacement and Reconstruction DevicesSubindustry352015101520Treatment DevicesSubindustry352015102010General Surgical DevicesSubindustry352015102015Other Surgical DevicesSubindustry352015102020Surgical Robotic SystemsSubindustry352015102020Surgical Robotic SystemsSubindustry352020151010Diversified Medical Devices and InstrumentsSubindustry352020151010Anesthesiology DevicesSubindustry352020151015Dental DevicesSubindustry352020151020Ear, Nose and Throat (ENT) DevicesSubindustry352020151025Plastic and Reconstructive Surgery DevicesSubindustry352020151030Radiology DevicesSubindustry352020151035Transfusion Medicine DevicesSubindustry352020151510Gastroenterology DevicesSubindustry352020151520Neurology DevicesSubindustry352020151520Neurology DevicesSubindustry352020151525Obstetrics and Gynecology DevicesSubindustry352020151530Oncology DevicesSubindustry352020151530Ophthalmology DevicesSubindustry352020151540Respiratory Devices			
Subindustry 352015101510 Joint Replacement and Reconstruction Devices Subindustry 352015101520 Other Orthopedics Devices Subindustry 352015102010 General Surgical Devices Subindustry 352015102015 Other Surgical Devices Subindustry 352015102020 Surgical Robotic Systems Subindustry 352015102020 Diversified Medical Devices and Instruments Subindustry 352020151010 Diversified Medical Devices and Instruments Subindustry 352020151010 Anesthesiology Devices Subindustry 352020151020 Ear, Nose and Throat (ENT) Devices Subindustry 352020151025 Plastic and Reconstructive Surgery Devices Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151520 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151535 Ophthalmology Devices	Subindustry	352015101010	Cardiology Non-Surgical Devices
Subindustry 352015101515 Other Orthopedics Devices Subindustry 352015102010 General Surgical Devices Subindustry 352015102015 Other Surgical Devices Subindustry 352015102020 Surgical Robotic Systems Subindustry 352015102020 Diversified Medical Devices and Instruments Subindustry 352020151010 Diversified Medical Devices and Instruments Subindustry 352020151010 Anesthesiology Devices Subindustry 352020151025 Dental Devices Subindustry 352020151020 Ear, Nose and Throat (ENT) Devices Subindustry 352020151025 Plastic and Reconstructive Surgery Devices Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151530 Ophthalmology Devices	Subindustry	352015101015	Cardiology Surgical Devices
Subindustry 352015101520 Treatment Devices Subindustry 352015102010 General Surgical Devices Subindustry 352015102020 Other Surgical Devices Subindustry 352015102020 Surgical Robotic Systems Subindustry 352020151010 Diversified Medical Devices and Instruments Subindustry 352020151010 Anesthesiology Devices Subindustry 352020151015 Dental Devices Subindustry 352020151020 Ear, Nose and Throat (ENT) Devices Subindustry 352020151025 Plastic and Reconstructive Surgery Devices Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151520 Neonatology Devices Subindustry 352020151520 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151530 Oncology Devices	Subindustry	352015101510	Joint Replacement and Reconstruction Devices
Subindustry352015102010General Surgical DevicesSubindustry352015102020Other Surgical DevicesSubindustry352015102020Surgical Robotic SystemsSubindustry352015151010Diversified Medical Devices and InstrumentsSubindustry352020151010Anesthesiology DevicesSubindustry352020151015Dental DevicesSubindustry352020151020Ear, Nose and Throat (ENT) DevicesSubindustry352020151025Plastic and Reconstructive Surgery DevicesSubindustry352020151030Radiology DevicesSubindustry352020151035Transfusion Medicine DevicesSubindustry352020151510Gastroenterology DevicesSubindustry352020151515Neonatology DevicesSubindustry352020151520Neurology DevicesSubindustry352020151525Obstetrics and Gynecology DevicesSubindustry352020151530Oncology DevicesSubindustry352020151530Oncology DevicesSubindustry352020151535Ophthalmology Devices	Subindustry	352015101515	Other Orthopedics Devices
Subindustry 352015102015 Other Surgical Devices Subindustry 352015102020 Surgical Robotic Systems Subindustry 352015151010 Diversified Medical Devices and Instruments Subindustry 352020151010 Anesthesiology Devices Subindustry 352020151015 Dental Devices Subindustry 352020151020 Ear, Nose and Throat (ENT) Devices Subindustry 352020151025 Plastic and Reconstructive Surgery Devices Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151520 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151530 Ophthalmology Devices	Subindustry	352015101520	Treatment Devices
Subindustry 352015102020 Surgical Robotic Systems Subindustry 352015151010 Diversified Medical Devices and Instruments Subindustry 352020151010 Anesthesiology Devices Subindustry 352020151015 Dental Devices Subindustry 352020151020 Ear, Nose and Throat (ENT) Devices Subindustry 352020151025 Plastic and Reconstructive Surgery Devices Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151530 Ophthalmology Devices	Subindustry	352015102010	General Surgical Devices
Subindustry 352020151010 Diversified Medical Devices and Instruments Subindustry 352020151010 Anesthesiology Devices Subindustry 352020151015 Dental Devices Subindustry 352020151020 Ear, Nose and Throat (ENT) Devices Subindustry 352020151025 Plastic and Reconstructive Surgery Devices Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151520 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151530 Ophthalmology Devices	Subindustry	352015102015	Other Surgical Devices
Subindustry 352020151010 Anesthesiology Devices Subindustry 352020151015 Dental Devices Subindustry 352020151020 Ear, Nose and Throat (ENT) Devices Subindustry 352020151025 Plastic and Reconstructive Surgery Devices Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151535 Ophthalmology Devices	Subindustry	352015102020	Surgical Robotic Systems
Subindustry 352020151020 Ear, Nose and Throat (ENT) Devices Subindustry 352020151025 Plastic and Reconstructive Surgery Devices Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151520 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151530 Ophthalmology Devices	Subindustry	352015151010	Diversified Medical Devices and Instruments
Subindustry 352020151020 Ear, Nose and Throat (ENT) Devices Subindustry 352020151025 Plastic and Reconstructive Surgery Devices Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151535 Ophthalmology Devices	Subindustry	352020151010	Anesthesiology Devices
Subindustry 352020151025 Plastic and Reconstructive Surgery Devices Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151535 Ophthalmology Devices	Subindustry	352020151015	Dental Devices
Subindustry 352020151030 Radiology Devices Subindustry 352020151035 Transfusion Medicine Devices Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151535 Ophthalmology Devices	Subindustry	352020151020	Ear, Nose and Throat (ENT) Devices
Subindustry352020151035Transfusion Medicine DevicesSubindustry352020151510Gastroenterology DevicesSubindustry352020151515Neonatology DevicesSubindustry352020151520Neurology DevicesSubindustry352020151525Obstetrics and Gynecology DevicesSubindustry352020151530Oncology DevicesSubindustry352020151535Ophthalmology Devices	Subindustry	352020151025	Plastic and Reconstructive Surgery Devices
Subindustry 352020151510 Gastroenterology Devices Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151535 Ophthalmology Devices	Subindustry	352020151030	Radiology Devices
Subindustry 352020151515 Neonatology Devices Subindustry 352020151520 Neurology Devices Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151535 Ophthalmology Devices	Subindustry	352020151035	Transfusion Medicine Devices
Subindustry 352020151520 Neurology Devices Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151535 Ophthalmology Devices	Subindustry	352020151510	Gastroenterology Devices
Subindustry 352020151525 Obstetrics and Gynecology Devices Subindustry 352020151530 Oncology Devices Subindustry 352020151535 Ophthalmology Devices	Subindustry	352020151515	Neonatology Devices
Subindustry 352020151530 Oncology Devices Subindustry 352020151535 Ophthalmology Devices	Subindustry	352020151520	Neurology Devices
Subindustry 352020151535 Ophthalmology Devices	Subindustry	352020151525	Obstetrics and Gynecology Devices
	Subindustry	352020151530	Oncology Devices
Subindustry 352020151540 Respiratory Devices	Subindustry	352020151535	Ophthalmology Devices
	Subindustry	352020151540	Respiratory Devices



Subindustry	352020151545	Urology Devices
Subindustry	352020151550	Vascular Devices
Subindustry	451020201510	Biotechnology and Genomics (GMO/Hybrids) Products



CONTACT

Solactive AG German Index Engineering

Platz der Einheit 1 60327 Frankfurt am Main Germanv

Tel.: +49 (0) 69 719 160 00
Fax: +49 (0) 69 719 160 25
Email: info@solactive.com
Website: www.solactive.com

© Solactive AG